Skip To Main Content
Pim P. van de Donk on Muck Rack

Pim P. van de Donk

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Pim P.

Contact Pim P., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Programmed death ligand 1 (PD-L1) PET/CT imaging to evaluate tumour saturation during atezolizumab treatment

|
By Jahlisa S. Hooiveld-Noeken, Iris C. Kok, Adrienne H. Brouwers, Sjoukje F. Oosting, Frederike Bensch, Lotte Smit, Carolien P. Schröder, Mathilde Jalving, Sjoerd G. Elias, Jourik A. Gietema, Simon Williams Verified, Elisabeth de Vries, Pim P. van de Donk, Laura Kist de Ruijter, Claudia A. J. van Winkel, Danique Giesen, Marjolijn N. Lub-de Hooge, Regula J. Deurloo, Alexander Ungewickell, Derk-Jan A. de Groot
| Nature Verified
Abstract Little is known regarding tumour target saturation by the programmed death-ligand (PD-L1) antibody atezolizumab. Therefore, tumour saturation by the PD-L1 antibody atezolizumab in patients with advanced solid tumours was assessed using 89Zr-atezolizumab PET imaging. Patients received 10 mg 89Zr-atezolizumab after the initial 2 cycles of 1200 mg atezolizumab, followed by PET/CT scans.
Open in Who Shared Issue with article?
See all 1 articles